# Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

> **NCT03346057** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 344 (actual)

## Conditions studied

- Reversal of Neuromuscular Blockade

## Interventions

- **DRUG:** Sugammadex 2 mg/kg
- **DRUG:** Sugammadex 4 mg/kg
- **DRUG:** Sugammadex 16 mg/kg
- **DRUG:** Neostigmine + Glycopyrrolate
- **DRUG:** Rocuronium
- **DRUG:** Vecuronium

## Key facts

- **NCT ID:** NCT03346057
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2019-09-04
- **Final completion:** 2019-09-04
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346057, "Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03346057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*